Developing a new therapeutic for childhood acute myeloid leukaemia
Dr Mingfeng Yu
University of South Australia
In Australia, acute myeloid leukaemia (AML) is the second leading cause of cancer death in children. Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are the most frequent genetic alterations in AML, and are associated with poor prognosis. Thus, FLT3 has emerged as a therapeutic target for treating AML. We have recently identified a highly potent FLT3 inhibitor that displays a selectivity for this kinase superior to known FLT3 inhibitors under development. This project will further evaluate the anti-cancer efficacy of this inhibitor in animal models of AML, and a successful outcome will support its advancement for treating childhood AML.